Treatment of steroid-resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563).
Hertenstein
B
B
Department of Internal Medicine III (Hematology and Oncology), University of Ulm, Germany.
Stefanic
M
M
Sandherr
M
M
Bunjes
D
D
Mertens
T
T
Arnold
R
R
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D004351:Drug Resistance; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D012008:Recurrence; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2; C079843:inolimomab